DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Yes — and unlike most articles, here are the exact figures from the body-composition substudies: about 40% of the weight lost on semaglutide and about 25% on tirzepatide was lean mass, not fat. What that means, why the drugs differ, and the evidence-based way to keep your muscle.
“Ozempic causes muscle loss” is repeated everywhere without a single figure. Here are the real ones, from the drugs’ own DEXA and MRI body-composition substudies. On semaglutide (STEP-1), total fat mass fell about 19% and lean mass about 10% from baseline — meaning roughly 40–45% of the total weight lost was lean tissue. On tirzepatide (SURMOUNT-1), the split was more favorable: at 72 weeks, body weight fell 21.3%, fat mass 33.9%, and lean mass 10.9% — about 25% of the loss was lean. So the honest framing is “25–40% of the weight comes from lean mass if you do nothing to protect it,” not “the drug melts your muscle.”
| Drug (substudy) | Fat mass change | Lean mass change | Share of loss that was lean |
|---|---|---|---|
| Semaglutide (STEP-1) | −19% | −10% | ~40–45% |
| Tirzepatide (SURMOUNT-1) | −33.9% | −10.9% | ~25% |
This is the counterintuitive part: tirzepatide (Zepbound, Mounjaro) produces more total weight loss than semaglutide, yet a smaller proportion of it is muscle — about 25% versus 40–45%. The leading explanation is its dual GIP/GLP-1 mechanism and the larger fat-mass reduction, which shifts the fat-to-lean ratio in your favor. Both drugs still cost you some lean mass; tirzepatide simply does it in a better ratio. See Wegovy vs Zepbound for the full head-to-head.
Three levers, in order of impact. 1) Protein. Clinical guidance for weight loss points to roughly 1.2–1.6 grams per kilogram of body weight per day — well above the standard 0.8 g/kg. On a GLP-1 this is genuinely hard because your appetite is suppressed, so treat protein as the priority at every meal (see high-protein foods). 2) Resistance training, 2–3 times a week: loading a muscle is the single strongest signal to your body to keep it. 3) Don’t lose faster than you need to, and track composition, not just the scale — a DEXA or InBody scan shows fat-versus-lean, so you can catch excess muscle loss the scale hides. Our weight-loss projector includes a lean-mass overlay so you can see the fat-versus-muscle split of your projected loss.
A new drug class aims to fix the muscle problem directly — but none is FDA-approved, and they exist only in trials today. Bimagrumab (an activin-receptor antibody) combined with semaglutide produced about 22% weight loss at 72 weeks in the Phase 2 BELIEVE study, with roughly 92% of the loss from fat; bimagrumab alone actually increased lean mass by about 2.5%. Regeneron’s trevogrumab (a myostatin antibody) in the Phase 2 COURAGE trial spared an estimated 50–80%of the lean mass otherwise lost with semaglutide. Promising — but these are investigational, and anyone selling “muscle-preserving peptides” alongside a grey-market GLP-1 is not offering these trial drugs.
Some muscle loss is unavoidable with meaningful weight loss, and the GLP-1 numbers (~25–40% of the loss) are in the expected range — not evidence the drugs are uniquely harmful. What determines your outcome is not really which drug you take but whether your program protects muscle: enough protein, resistance training, and sensible pacing. Do those, and the weight you lose is mostly the fat you wanted to lose.